Alnylam Pharmaceuticals
ALNY
#601
Rank
NZ$57.74 B
Marketcap
$447.73
Share price
4.37%
Change (1 day)
47.83%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.55

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$7.33. In 2022 the company made an earnings per share (EPS) of -$16.57 a decrease over its 2021 EPS that were of -$12.84.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.55-60.45%
2022-$16.5729.03%
2021-$12.84-3.36%
2020-$13.29-8.48%
2019-$14.527.67%
2018-$13.4839.74%
2017-$9.6512.94%
2016-$8.5438.84%
2015-$6.15-32.88%
2014-$9.17259.44%
2013-$2.55-31.25%
2012-$3.7152.94%
2011-$2.4330.77%
2010-$1.86-8.77%
2009-$2.0378.13%
2008-$1.14-70.78%
2007-$3.9199.09%
2006-$1.96-43.88%
2005-$3.50-82.33%
2004-$19.79-59.23%
2003-$48.53

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$3.03-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$66.64-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.97 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.48-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$3.01-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.67-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$5.67-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.57-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel